Currently, there are 598.99M common shares owned by the public and among those 588.46M shares have been available to trade.
The company’s stock has a 5-day price change of 0.00% and 18.29% over the past three months. MPW shares are trading -1.22% year to date (YTD), with the 12-month market performance down to -44.89% lower. It has a 12-month low price of $2.92 and touched a high of $10.74 over the same period. MPW has an average intraday trading volume of 16.97 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -4.77%, -0.97%, and 4.51% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Medical Properties Trust Inc (NYSE: MPW) shares accounts for 73.35% of the company’s 598.99M shares outstanding.
It has a market capitalization of $2.91B and a beta (3y monthly) value of 1.31. The earnings-per-share (ttm) stands at -$2.44. The company has a debt-to-equity ratio at 1.51. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.68% over the week and 4.05% over the month.
Earnings per share for the fiscal year are expected to increase by 61.48%, and 216.32% over the next financial year.
Looking at the support for the MPW, a number of firms have released research notes about the stock. Deutsche Bank stated their Hold rating for the stock in a research note on April 17, 2024, with the firm’s price target at $5. Colliers Securities coverage for the Medical Properties Trust Inc (MPW) stock in a research note released on April 10, 2024 offered a Neutral rating with a price target of $4.25. Exane BNP Paribas was of a view on March 01, 2024 that the stock is Outperform, while Deutsche Bank gave the stock Sell rating on January 30, 2024, issuing a price target of $2. KeyBanc Capital Markets on their part issued Sector Weight rating on January 05, 2024.
